Figure 3 from Targeting PRMT1 Reduces Cancer Persistence and Tumor Relapse in EGFR- and KRAS-Mutant Lung Cancer
Year: 2025
Type: other
Abstract: PRMT1 knockdown enhances tumor regression in EGFRmut and KRASG12C lung cancer xenograft models. A and B, EGFRmut lung cancer cells HCC827 (A) and KRASG12Clung cancer cells H1373 (B) were engineered to express PRMT1-targeting shRNA and subcutaneously injected into the flanks of nude mice. Once tumors reached an average volume of 500 mm3 (dashed lines), animals were randomly assigned to different groups (8–10 animals per group) and began receiving doxycycline (Dox, 1 mg/mL) in drinking water. After 3 days of Dox treatment to ensure PRMT1 knockdown, daily oral administration of either vehicle or targeted drugs began: 5 mg/kg osimertinib (Osi) for HCC827 and 100 mg/kg sotorasib (Soto) for H1373. Treatment with vehicle or targeted drugs was discontinued at the residual disease stage, whereas Dox administration continued until the end of the study. The dosing schedules of targeted drugs are marked with gray triangles. Tumor volumes were measured biweekly, and the data are presented as mean ± standard error. C and D, Tumor volumes of HCC827 (C) and H1373 (D) xenografts were normalized to baseline at randomization (dashed line) for each animal. Statistical comparisons between groups were based on the integrated tumor volume over time (area under curve; AUC), using one-sided Mann–Whitney tests. The significance of the results is indicated by symbols: *, P ≤ 0.05; **, P ≤ 0.01. E and F, Waterfall plots show the percentage change in tumor volume from baseline for individual animals at the conclusion of HCC827 (E) and H1373 (F) studies.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4406630748